SCHEMBL4589250

SCHEMBL4589250

NC(=O)NCCCI

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15216237 0.92
SCHEMBL16847555 0.83
SCHEMBL1309431 0.83 TDP1 (0.42)
SCHEMBL1837224 0.83 KDM4E (0.48)
SCHEMBL4682290 0.81
SCHEMBL1837168 0.80 KDM4E (0.52)
SCHEMBL11173620 0.80 KDM4E (0.52)
SCHEMBL1839119 0.80 KDM4E (0.52)
SCHEMBL28622543 0.80 KDM4E (0.52)
SCHEMBL1309360 0.80 KDM4E (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024081668-A2 LIPID-POLYMER COMPOUNDS, COMPOSITIONS, AND USES THEREOF MIRUS BIO LLC (US) 2024-04-18 WO disclosed
WO-2023156629-A1 STEALTH-STABILIZED LIPO-POLYAMINO ACIDS POLYPEPTIDE THERAPEUTIC SOLUTIONS, S.L. (ES) 2023-08-24 WO disclosed
WO-2023111290-A1 POLYSARCOSINE-VITAMIN E DERIVATIVES POLYPEPTIDE THERAPEUTIC SOLUTIONS, S.L. (ES) 2023-06-22 WO disclosed
US-11364189-B2 Method for the treatment of keratin materials using amide C-glycoside derivatives, and cosmetic composition containing same L'OREAL (FR) 2022-06-21 US disclosed
US-20210000727-A1 DITHIAZOCANE COMPOUNDS FOR THE COSMETIC USE THEREOF L'OREAL (FR) 2021-01-07 US disclosed
US-20190274940-A1 METHOD FOR THE TREATMENT OF KERATIN MATERIALS USING AMIDE C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME L'OREAL (FR) 2019-09-12 US disclosed
US-20190263770-A1 METHOD FOR THE TREATMENT OF KERATIN MATERIALS USING ACID, ESTER OR AMIDE C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME L'OREAL (FR) 2019-08-29 US disclosed
EP-3165532-A2 AURISTATIN DERIVATIVES, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES Industrial Technology Research Institute (TW) 2017-05-10 EP disclosed
WO-2016149464-A1 AMINO ACID ACYLATION REAGENTS AND METHODS OF USING THE SAME REGENERON PHARMACEUTICALS, INC. (US) 2016-09-22 WO disclosed
EP-2966063-A1 FUNGICIDAL PYRAZOLES E. I. du Pont de Nemours and Company (US) 2016-01-13 EP disclosed
US-6573266-B1 Compounds used for treating multitiple sclerosis and encephalomyelitis SCHERING AKTIENGESELLSCHAFT (DE) 2003-06-03 US disclosed
US-6555537-B2 Inhibit activity of chemokines, macrophage inflammatory protein-1 (MIP-1 alpha) and RANTES; 1-((4-chlorophenoxy)methyl)-carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine for example SCHERING AKTIENGESELLSCHAFT (DE) 2003-04-29 US disclosed
US-6541476-B1 Treating multiple sclerosis or encephalomyelitis in a human SCHERING AKTIENGESELLSCHAFT (DE) 2003-04-01 US disclosed
US-6534509-B1 Derivatives are useful as anti-inflammatory agents. This invention is also directed to pharmacetutical compostions for inflammation SCHERING AKTIENGESELLSCHAFT (DE) 2003-03-18 US disclosed
EP-0988292-B1 PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS SCHERING AG (DE) 2003-02-12 EP disclosed
US-20020177598-A1 Piperazine derivatives and their use as anti-inflammatory agents SCHERING AKTIENGSCHELLSCHAFT 2002-11-28 US disclosed
EP-1254899-A2 Piperazine derivatives and their use as anti-inflammatory agents Schering Aktiengesellschaft (DE) 2002-11-06 EP disclosed
US-6207665-B1 TO TREAT INFLAMMATORY DISORDERS IN HUMANS SCHERING AKTIENGESELLSCHAFT (DE) 2001-03-27 US disclosed
EP-0988292-A2 PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2000-03-29 EP disclosed
WO-1998056771-A2 PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 1998-12-17 WO disclosed